DeutschNewstral
Article
jdsupra.com on 2021-05-13 17:55
Alvotech Files Suit Against AbbVie to Invalidate Humira Patent Portfolio
Related news
- AbbVie Files Second Suit Against Alvotech For Patent Infringement Under the BPCIAjdsupra.com
AbbVie, Boehringer Settle U.S. Patent Dispute Over Drug Humirawsj.com- AbbVie Inc. et al. v. Alvotech hf. Updatesjdsupra.com
- Alvotech Broadens Access to HUMIRA (adalimumab) Biosimilarsjdsupra.com
- Litigation Update: AbbVie v. Alvotech hf (Adalimumab)jdsupra.com
- Alvotech and STADA Launch HUKYNDRA® (Biosimilar of HUMIRA®) in Europejdsupra.com
- The Strategies AbbVie Employed to Protect Humira From Copycatswsj.com
- AbbVie Sues Amgen On 10 Of 100 Humira Patentsjdsupra.com
- AbbVie Allegations of Trade Secret Misappropriation by Alvotech hf.jdsupra.com
AbbVie sues to fend off copy of Humira drugdailyherald.com- Coherus Challenges One AbbVie Humira Patent In Four PTAB Proceedingsjdsupra.com
- First High-Concentration Humira® Interchangeable, Alvotech and Teva’s Simlandi®, Approved in the U.S.jdsupra.com
- No Antitrust Violations for Creating and Enforcing Humira Patent Thicketjdsupra.com
- In the Weeds? Humira “Patent Thicket” Isn’t an Antitrust Violationjdsupra.com
- HUMIRA® Biosimilar Update -- Settlement in AbbVie v. Amgen Case Announced and AbbVie v. Boehringer Ingelheim Litigation Beginsjdsupra.com
- AbbVie Grants Momenta Global Patent Licenses for Biosimilar of HUMIRA (Adalimumab)jdsupra.com
- MAbbVie stock ticks higher as Humira patent dispute with Novartis resolvedmarketwatch.com
- INSIGHT: Abbvie Defeats Novel Antitrust Claims Against Humira Patent Estate—Lessons Learnedjdsupra.com
- Celltrion to Enter U.S. Humira Biosimilar Market Following Patent Agreement with AbbViejdsupra.com
- 7th Circuit Hears Oral Arguments in Humira “Patent Thicket” Antitrust Casejdsupra.com